Health
Alnylam Soars After Drug Meets Goal in Heart Disease Trial
- Company’s Amvuttra reduces patient deaths and hospitalizations
- CEO touts ‘multibillion-dollar opportunity’ from expanded use
The Alnylam Pharmaceuticals Inc. offices, Cambridge, Massachusetts.
Photographer: Adam Glanzman/BloombergThis article is for subscribers only.
Alnylam Pharmaceuticals Inc. shares soared after its drug succeeded in treating a progressive and deadly form of heart disease, potentially opening up a new avenue for the company’s top-selling product.
A study released Monday found that Alnylam’s vutrisiran, which is sold as Amvuttra, helped patients with a serious heart condition known as known as ATTR amyloidosis with cardiomyopathy. The goal of the study was for the drug to reduce death and hospitalizations in patients with the condition who were taking a Pfizer Inc. drug approved for it, as well as in those not on Pfizer’s drug.